Rapport Therapeutics, Inc. (RAPP)
26.07
+1.63
(+6.67%)
USD |
NASDAQ |
Nov 09, 16:00
26.03
-0.04
(-0.15%)
After-Hours: 20:00
Rapport Therapeutics Total Liabilities (Quarterly) : 27.37M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 27.37M |
| June 30, 2026 | 36.06M |
| March 31, 2026 | 26.08M |
| December 31, 2025 | 27.78M |
| September 30, 2025 | 23.71M |
| June 30, 2025 | 21.98M |
| Date | Value |
|---|---|
| March 31, 2025 | 16.22M |
| December 31, 2024 | 9.506M |
| September 30, 2024 | 8.03M |
| June 30, 2024 | 9.212M |
| March 31, 2024 | 11.18M |
| December 31, 2023 | 14.48M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Johnson & Johnson | 115.90B |
| ANI Pharmaceuticals, Inc. | 930.55M |
| Corcept Therapeutics, Inc. | 200.29M |
| Veru, Inc. | 8.651M |
| Eli Lilly & Co. | 107.80B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 418.56M |
| Shareholders Equity (Quarterly) | 391.19M |
| Debt to Equity Ratio | 0.024 |
| Current Ratio | 20.07 |
| Net Debt Paydown Yield | 0.03% |